



***BioAlliance Pharma Announces Shareholders' Meeting and  
Appointment of Russell Greig and Danièle Guyot-Caparros  
As Independent Board Members***

**Paris, June 27, 2013** - BioAlliance Pharma SA (Euronext Paris - BIO), a Company dedicated to the development of orphan oncology products and supportive care products, announces that it held its shareholders' meeting at its headquarters on June 26, 2013.

As a result of the shareholder's meeting, Dr Russell Greig and Danièle Guyot-Caparros have been appointed as independent Board Members, replacing respectively Michel Arié and Catherine Dunand whose mandate expired today.

Dr Russell Greig holds a PhD in biochemistry from the University of Manchester. He held strategic positions at GlaxoSmithKline (GSK) for nearly three decades, notably as President of GSK Pharmaceuticals International from 2003 to 2008 and as a member of GSK Corporate Executive Team. Most recently, he served as President of SR One, GSK's Corporate Venture Group. Since 2012, Russell has been a permanent guest member of the Board of Directors and has brought particular expertise to the Company in the area of Strategic Planning and Corporate Development.

Danièle Guyot-Caparros graduated from the Ecole Supérieure de Commerce of Nancy in finance and accounting. Following international missions in Audit, she joined Rhone Poulenc (now Sanofi) where she has held different positions with an increasing scope of responsibilities in finance on a European level and in business planning and performance monitoring on a worldwide level. Danièle has been working as a consultant specialized in life sciences and healthcare areas for 5 years.

*"We are delighted to have Danièle and Russell joining our Board. Their appointment is in line with the Board's expansion to international profiles and reinforces its skills in finance and strategy areas as well as its expertise in the pharmaceutical and biotechnology areas,"* declared Judith Greciet, CEO of BioAlliance Pharma.

*"I would like to join Judith in welcoming Danièle and Russell and warmly thank both departing members of the Board of Directors, Catherine and Michel, who brought their great professional experience to the Company these past few years. With its various backgrounds and skills, the new Board will actively pursue its role in defining and implementing the Company's strategy and supporting its management team,"* added Patrick Langlois, Chairman of the Board of Directors of BioAlliance Pharma.

As of today, BioAlliance Pharma's Board of Directors is composed of:

- Patrick Langlois, Chairman of the Board of Directors and independent Board Member
- Judith Greciet, Chief Executive Officer and Board Member
- Russell Greig, independent Board Member

- Danièle Guyot-Caparros, independent Board Member
- Thomas Hofstaetter, independent Board Member
- David H. Solomon, independent Board Member
- Financière de la Montagne, represented by Nicolas Trebouta, Board Member
- Kurma Life Sciences Partners, represented by Rémi Droller, Board Member

Complete voting results of the Combined Shareholders Meeting are available on our website at [www.bioalliancepharma.com](http://www.bioalliancepharma.com), section Investors/Shareholders' meeting.

### **About BioAlliance Pharma**

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

#### **Specialty products**

Loramyc<sup>®</sup>/Oravig<sup>®</sup> (oropharyngeal candidiasis in immunocompromised patients): Registered in 26 countries (EU, US, Korea), commercialized in Europe and in the US.

Sitavig<sup>®</sup> (Acyclovir Lauriad<sup>®</sup>) (labialis herpes): Registered in the US and in 8 European countries, registration status in the other European countries.

Fentanyl Lauriad<sup>®</sup> (chronic cancer pain): Positive preliminary Phase I results

#### **Orphan Oncology products**

Livatag<sup>®</sup> (Doxorubicin Transdrug<sup>™</sup>) (primary liver cancer): Phase III on going

Validive<sup>®</sup> (Clonidine Lauriad<sup>™</sup>) (mucositis): Phase II on going

AMEP<sup>®</sup> (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at [www.bioalliancepharma.com](http://www.bioalliancepharma.com)

### **Disclaimer**

*This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

*For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2012 Reference Document filed with the AMF on April 18, 2013, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website (<http://www.bioalliancepharma.com>).*

#### **BioAlliance Pharma SA**

Judith Greciet, CEO  
Tel +33 1 45 58 76 00  
[judith.greciet@bioalliancepharma.com](mailto:judith.greciet@bioalliancepharma.com)

#### **ALIZE RP**

Caroline Carmagnol  
Tel.: +33 6 64 18 99 59  
[caroline@alizerp.com](mailto:caroline@alizerp.com)

Nicolas Fellmann, CFO  
Tel.: +33 1 45 58 71  
[nicolas.fellmann@bioalliancepharma.com](mailto:nicolas.fellmann@bioalliancepharma.com)

Christian Berg  
Tel: +33 1 43 43 40 46  
[christian@alizerp.com](mailto:christian@alizerp.com)